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Abstract Ongoing debates about the need and extent of
planned neck dissection (PND), and required nodal ra-
diation doses volumes lead to this evaluation. Aim was to
assess nodal control after definitive intensity modulated
radiation therapy (IMRT ± systemic therapy) followed by
PND in our head neck cancer cohort with advanced nodal
disease. Between 01/2005 and 12/2013, 99 squamous cell
cancer HNC patients with pre-therapeutic nodal metastasis
C3 cm were treated with definitive IMRT followed by
PND. In addition, outcome in 103 patients with nodal re-
lapse after IMRT and observation only (no-PND cohort)
were analyzed. Prior to PND, PET–CT, fine needle aspi-
rations, ultrasound and palpation were assessed regarding
its predictive value. Patterns of nodal relapse were assessed
in patients with isolated neck failure after definitive IMRT
alone. 70/99 (70 %) PND specimens showed histopatho-
logical complete response (hCR), which translated into
statistically significantly superior survival compared with
partial response (hPR) with 4-year overall survival, disease
specific survival and nodal control rates of 90/83/96 vs
67/60/78 % (p = 0.002/0.001/0.003). 1/99 patient
developed isolated subsequent nodal disease. 64/2147 re-
moved nodes contained viable tumor (3 %). Predictive
information of the performed diagnostic investigations was
not reliable. 17/70 hCR patients showed true negative
findings in available three to four investigations (0/29
hPR). 27/103 no-PND patients developed isolated neck
disease (26 %) with successful salvage in 21/24 [88 %, or
21/27 (78 %)]. Nearly all failures occurred in the prior
nodal gross tumor volume area. A more restrictive ap-
proach regarding PND and/or nodal IMRT dose-volumes
may be justified.
Keywords Planned neck dissection  PND  Elective
nodal volume and radiation  Isolated nodal failure  Nodal
IMRT
Introduction
In several publications, low isolated neck recurrence rates
after irradiation (±chemotherapy) of *\5 % is reported
[1–6]. Main question is, if full radiation dose aiming a
biological dose equivalent of *70 Gy to nodal metastases
with more or less extended elective irradiation of the
lymphatic pathways, combined with systemic therapy in
most cases, followed by planned neck dissection (PND),
may or not be needed [1, 7, 8]. According to our internal
guidelines, PND in all patients with initial nodal disease
[3 cm referred for definitive intensity modulated radiation
therapy (IMRT ± systemic therapy) was provided since
2005.
Aim was to assess the outcome in this cohort. We
evaluated the rate of residual disease in PND specimens
and predictive values for complete remission of positron
emission tomography–computed tomography (PET–CT),
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fine needle aspiration (FNA), ultrasound (US) and clinical
palpation of the neck prior to PND.
In addition, the pattern of nodal relapses was assessed in
cN? (any nodal size) patients with neck failure after
definitive IMRT followed by observation only (no-PND
cohort). Hypothesis was that de-intensivation of neck
treatment may be an option.
Methods
All patients were identified from a prospective data base.
Ethical approval for IMRT cohort analysis is available.
Histopathological disease control in the PND cohort, nodal
failure patterns in PND and no-PND patients (localization
in the prior nodal gross tumor volume (GTV) inside the
boost planning target volume (PTV), vs inside the inter-
mediate or elective PTV, vs outside of any treatment vol-
umes, respectively), and rates of isolated nodal failure and
its successful salvage in both cohorts was assessed.
Patients
Between 01/2005 and 12/2013, 99 HNC patients with
cervical lymph node metastases C3 cm were treated with
definitive IMRT ± systemic therapy followed by PND.
Patient and tumor characteristics are shown in Tables 1, 2.
In addition, our no-PND cohort with proven nodal re-
lapse/progress following definitive IMRT (103 of 718
IMRT patients (14 %)) treated between 02/2002 and
12/2013 was analyzed, Table 1. Reasons for no previous
PND in those patients were: treatment prior to 2005
(n = 13), cN?\3 cm (n = 31), early salvage surgery for
clinical or radiological high suspicion for/proven loco-
regional persistence (n = 41), or patients’ preference or
comorbidity or age (19).
IMRT
Treatment plans were calculated by the Varian Treatment
Planning System (Eclipse External Beam Planning Sys-
tem, Version 7.3.10 and PRO 8.9, AAA 8.9, Varian
Medical Systems). Simultaneously integrated boost (SIB)–
IMRT was performed using the following schedules (for
more details see former publications [9])
Definitive IMRT
• SIB2.00: Daily dose of 2.00 Gy (PTV1)/1.70 Gy
(PTV2)/1.54 Gy (PTV3) to a total dose of 70.00 Gy
(5 fractions/week).
• SIB2.11: Daily dose 2.11 Gy (PTV1)/1.80 Gy (PTV2)/
1.64 Gy (PTV3) to a total dose of 69.60 Gy (5
fractions/week).
• SIB2.2: Daily dose 2.2 Gy (PTV1)/2.0 Gy (PTV2)/
1.64 Gy (PTV3) to a total dose of 66.0 Gy (5 fractions/
week).
The elective nodal treatment volume was mostly cov-
ered by 54 Gy in 33–35 fractions; nodal metastases were
treated with 70 Gy to the nodal high-dose planning target
volume [PTV, 8–12 (-15) mm margin around nodal gross
tumor volumes].
Concomitant systemic therapy
Cisplatin was given in weekly doses of 40 mg/m2 at 1 day
a week. Since 04/2006, cetuximab (400 mg/m2 loading
dose, followed by 250 mg/m2 at 1 day a week) was used in
patients with contra-indications for concomitant standard
Table 1 Cohort characteristics
Parameters PND cohort (N = 99) No-PND cohort with nodal failure (N = 103)
Gender (f:m) 21:78 (1:3.7) 1:4.1
Mean age at initial treatment (range) 61 (41–83) 61 (27–91)
Mean follow-up, (months/range) 49 (6–107) 23 (2–100)
Squamous cell carcinoma histology 99 (100 %) 103 (100 %)
Diagnosis
Mesopharynx 69 (70 %) 53 (52 %)
Hypopharynx 19 (19 %) 21 (21 %)
Larynx 9 (9 %) 11 (10 %)
Unknown primary 2 (2 %) 1 (1 %)
Oral cavity 0 13 (12 %)
Nasopharynx 0 4 (4 %)
TN stages
T 1/2/3/4 18/42/14/25/0 7/26/20/41/9
N 0/1/2a/2b/2c/3/recurrence 0/2/9/48/32/8/0 0/10/3/37/42/5/6
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cisplatin chemotherapy. 87 and 82 % of the PND and no-
PND cohort underwent concomitant systemic treatment,
respectively.
Follow-up (FU) after IMRT
3–6 weeks after completion of IMRT, all patients were
regularly seen in our joint clinic at the Department of Head
and Neck or Maxillofacial Surgery. Institutional standards for
patient assessment included physical examination with addi-
tional flexible fiber-optic endoscopy approximately every
2 months in the first year of follow-up, every 3 months in the
second to third year, and every 6 months in the fourth to fifth
year. Most patients completed FU after 5 years of relapse free
observation. Our interdisciplinary in-house guidelines rec-
ommend an elective neck dissection in patients with initial
nodal metastasis[3 cm since 2005. All patients with per-
formed elective PND in the time interval between 3 and
18 weeks were included in this analysis. Patients with proven
persistent or early progressive disease based on clinical ex-
amination and/or imaging and/or histopathological prove
were not included in this PND evaluation (n = 7). Rates of
ultrasound, PET–CT, FNA performed are listed in Table 3.
Statistics
Statistical calculations were performed using the statistics
program implemented in StatView (version 4.5; SAS In-
stitute, Cary, NC). Univariate analyses were performed with
a Cox proportional hazards regression model in StatView.
Actuarial survival data were calculated using Kaplan–Meier
curves and log-rank tests implemented in StatView. p val-
ues\0.05 were considered statistically significant.
Results
Survival
PND cohort: when last time seen, 74 % were alive with no
evidence of disease, 7 % were alive with disease, 11 %
have died of disease, and 8 % have inter-currently died. In
65 %, PND was performed 3–8 weeks after IMRT com-
pletion, in 23 %, in the interval between[8 and 12 weeks,
in 11 %, the interval was[12–17 weeks.
no-PND cohort: 103/718 (14 %) of all patients with
nodal relapse following definitive IMRT ± systemic ther-
apy and observation only were assessed. In 39/103, per-
sistent nodal disease was diagnosed (persistence:
0–6 months post IMRT). The 4-year OAS was 73 %,
comparable to the PND cohort.
PND specimens
In 70/99 (70 %) patients, PND specimens showed
histopathological complete response (hCR), and in 29/99
(30 %) partial response (hPR), Table 2. Disease control
rates are listed in Table 4 and Fig. 1. 14/29 (48 %) hPR
patients and 9/70 (13 %) hCR patients experienced sub-
sequent distant and/or local and/or nodal failure.
In 16/29 hPR patients, the specimen contained one
single node with viable cells, in the remaining 13 patients,
2 (n = 6), 3 (n = 2), 4 (n = 3), 6 (n = 1) and 11 nodes
(n = 1) were found. 8/13 (62 %) developed distant and/or
local and/or nodal failure in the following 2–6 months,
which occurred in 6/16 (38 %) patients with only 1 positive
lymph node. 64/2124 removed nodes contained viable tu-
mor (3 %). 18/99 patients (18 %) underwent bilateral PND
(viable tumor in 4/18 (4 %); in all 4 patients both sides
were affected (8 hPR specimens out of totally 117 neck
dissection specimens, 7 %). The following levels were
removed in 81 patients with unilateral PND: level ll (2),
level lll (1), levels ll–lll (7), levels l–lll (2), levels ll–lV
(53), levels l–lV (12), levels ll–V (4).
Prediction of hPR in PND specimens
TN stage, nodal diameter or gross tumor volume were not
predictive for hPR. Table 3 shows results of the assessed
investigations. In 16/29 patients (55 %), a very low viable
tumor cell load was described in the histopathological re-
port (‘minimal viable residuals’ or ‘few viable cells left’);
Table 2 Disease characteristics
Disease parameters All PND (n = 99) hCR PND (n = 70) hPR PND (n = 29) p value
Largest node diameter 45.5 mm (30–86) 44.2 mm 48.6 mm NS
Volume of the largest node 21.1 cc (6–131) 20.5 cc 22.4 cc NS
Total initial nodal volume 31.5 cc (6–131) 29.3 cc 37.5 cc NS
T 1/2-3/4 18/56/25 11/39/20 7/18/5 NS
N 1-2b/2c/3 59/32/8 42/23/5 17/9/3 NS
Diagnosis
Hypopharynx 19 9 10 NS
Larynx 8 5 3 na
Oropharynx 72 56 16 NS
Eur Arch Otorhinolaryngol
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in 10 patients viable tumor areas in the range of one to
several millimeters were reported, in only 3 patients (10 %
of hPR, 3 % of the entire cohort), substantial viable tumor
persistence was found like soft tissue metastasis or several
necrotic lymph nodes with extra-capsular extension. In 2 of
these 3 patients, pre PND FNA and PET–CT were positive.
17/70 hCR patients (24 %) showed no signs of disease in
all (3–4 each) performed investigations; in the hPR cohort,
all patients presented with positive/highly suspicious find-
ings in at least one of their 1–4 investigations.
hCR translated in statistically significantly superior
outcome compared to hPR, Table 4 and Fig. 1. All out-
come parameters but local control were statistically sig-
nificantly different in favor of hCR.
Isolated nodal failure
Isolated nodal failure occurred in only 1/29 (3 %) patient
subsequently to PND (1/14 in the hPR subgroup). In the
no-PND cohort, 27/103 patients (26, or 4 % of the entire
IMRT cohort) presented with an isolated nodal relapse.
In 24/27 (89 %), salvage surgery was performed, in
21/24 (88 %) successfully: 6/27 (22 %) of the patients
with isolated nodal relapse have been lost, or 0.8 % of
all IMRT patients who underwent no PND (6/718).
Figure 2 gives an overview about the two analyzed co-
horts with respect to outcome in patients with isolated
nodal disease.
Site of nodal persistence
PND cohort: In 28/29 patients with a residuum in the hPR
specimen, residual disease was identified at the anatomical
site of the initially positive nodes; in 5 patients with ini-
tially advanced disease and substantial viable residuals,
disease was found at the original nodal gross tumor volume
as well as invading the environment.
no-PND cohort: 91 % (94/103) of the no-PND cohort
were diagnosed in the high-dose PTV where the initial
nodal GTV was located, in 3 % nodal relapse developed in
the intermediate or elective dose PTVs, in 6 % out of the
radiation PTVs. 26 of 27 patients with isolated nodal dis-
ease developed nodal failure in the high-dose area in/close
to the prior GTV, 1/27 developed in the elective PTV.
Table 3 Predictive value of
PET–CT and FNP in the
assessed cohort
All END (N = 99) hCR END (n = 70) hPR END (n = 29)
PET-CT
Available 68/99 (69 %) 50/70 (71 %) 18/29 (62 %)
Correct prediction 49/68 (72 %) CN: 43/50 (86 %) CP: 6/18 (33 %)
FNA
Available 50/99 (50 %) 35/70 (50 %) 15/29 (50 %)
Correct prediction 33/50 (66 %) CN: 27/35 (77 %) CP: 6/15 (40 %)
PET-CT ? FNA available 39/99 (39 %) 25/70 (36 %) 14/29 (48 %)
Both predictions correct 19/39 (49 %) CN: 15/25 (60 %) CP: 4/14 (29 %)
No PET-CT and no FNA available 21/99 (21 %) 13/70 (19 %) 8/29 (28 %)
Ultrasound
Available 80/99 (81 %) 66/70 (94 %) 24/29 (83 %)
Correct prediction 31/99 (31 %) CN: 8/66 (12 %) CP: 23/24 (96 %)
Cervical palpation
Information available 99/99 (100 %) 70/70 (100 %) 29/29 (100 %)
Correct prediction 61/99 (62 %) CN: 35/70 (50 %) CP: 26/29 (90 %)
No positive investigations 17/99 (17 %) 17/70 (24 %) Zero (0 %)
PND planned neck dissection, hCR histological complete remission, hPR histological partial remission, CN
correct negative, CP correct positive
Table 4 Disease control
4-Year outcome parameters hCR PND (n = 70) (%) hPR PND (n = 29) (%) p value
Local control rate 91 88 0.56
Nodal control rate 96 78 0.003
Distant metastastis free survival 95 71 0.0004
Disease specific survival 83 60 0.001
Overall survival 90 67 0.002
Eur Arch Otorhinolaryngol
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Discussion
Limitations of the present evaluation are––beside the ret-
rospective evaluation of the no-PND cohort––the aspect
that not all patients underwent FNA and/or PET-CT and/or
ultrasound prior to PND, as the indication for PND was
previously decided (‘planned’) based on the nodal metas-
tasis diameter.
An early analysis of failure patterns after definitive
IMRT of our first 280 patients [10] is included in this
recent analysis, with comparable nodal failure rate (11 vs
14 %).
In brief, we found
• 30 % of PND specimens in patients with nodal
metastasis[3 cm containing residual histopathological
disease
• 3 % of resected PND lymph nodes containing viable
tumor
• all hPR patients presented with 1–4 positive pre-
operative examination results (PET–CT, US, FNA,
palpation); 17 of the hCR group showed correct
negative findings in their 3–4 available examinations;
for this situation, the estimated risk to miss residual
disease by observation only would be *18 % (acc. to
the statistical ‘rule of three’ to estimate the probability
of adverse events in small sample sizes with few
events, giving the upper limit of the 95 % confidence
interval of the probability: 3/17)
• isolated neck relapse was diagnosed in 1 % subse-
quently to PND, in 27 % of our no-PND neck relapse
cohort, of which *80 % were successfully salvaged
• [95 % of all nodal failures/residua were found at the
site of prior nodal GTV.
Comparison with published data:
PND specimen
Our findings match well with recent published literature.
Response rates to radiation are reported to some degree in-
fluenced by the time gap between PND and completion of
radiation; however, there is considerable congruence with
published results from other centers. Goguen et al. [11] re-
ported a clinically complete response rate of 75 %
(61–85 %), Dautrement et al. [12] found 68 %, Cannady
et al. [3] 65 % hCR in 241 patients all with cN2–3 disease.
Ganly et al. [13] found 19/56 patients (33 %) with viable
tumor in their specimen of a comprehensive neck dissection
either as a planned or salvage procedure. Hamoir et al. [7]
conducted a recent literature review on the role of neck
dissection following chemo-radiation, and summarized the
Fig. 1 PND cohort: disease control
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reported rates of viable nodal tumor cells as follows: 40 %
(20–68 %) in cases of clinical partial nodal response, and
20 % (0–39 %) in cases of clinical complete response,
noting that the ranges may be explained by factors like the
interval between completion of radiation and END, or the
criteria to establish the viability of tumor cells. Most re-
cently, Huang et al. [14] reported on 291 patients treated
with PND after radiation alone or for radiologically diag-
nosed residual disease, finding 28 % with residual viable
tumor foci in the specimen.
Predictive parameters for hPR
FNA and PET–CT were limitedly reliable to predict hCR/
hPR, which is expectable, considering that 55 % of the spe-
cimens in our cohort contained only few viable cells. In ad-
dition, in 35 % viable tumor areas of several millimeters to
larger areas of the affected mostly substantially altered and
destroyed lymph nodes with no extra-capsular extension were
stated. This finding confirms review results published by
Hamoir et al. [7], who summarized reported data of a poor
correlation between physical examination plus CT and
pathological diagnosis (negative predictive value 33–44 %).
With respect to FDG–PET–CTs,we are facedwith conflicting
results from retrospective studies (different time intervals
from radiation, as one of several potential reasons) [7].
Hypopharynx carcinoma was reported baring a higher
risk as compared to other primary sites [1]. This was also
found in our cohort with however too small sample size to
rely on (10/19 hypopharynx cancer patients with hPR).
Survival benefit for hCR patients
Approximately 20 % survival benefit was similarly observed
by Soltys et al. [15] in patients who underwent neck dissec-
tion for clinically partial response, with 75 % (hCR) vs 42 %
(hPR) 5-year disease free survival. Ganly et al. [13] reported
5-year overall survival rates of 93 vs 49 % in favor of the
hCR subgroup, Lango et al. [16] found recurrence free sur-
vival rates of 85 vs 37 % for negative vs positive pathology.
Half of our patients with hPR subsequently developed
loco-regional and/or distant failure (15/29). Huang et al.
[14] similarly found 33 subsequent failures in 70 patients
with positive PND. The ultimate cure rate of patients with
viable nodal tumor is reported *30–50 % [13, 14, 16],
*66 % in the own cohort.
Fig. 2 Outcome in patients
with isolated nodal disease in
the two assessed cohorts
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Location of nodal residuum or relapse in the prior
GTV area
As a consequence of the known fact of most loco-regional
failures following definitive IMRT occurring in-field (in-
side the boost PTV) in the area of prior primary and nodal
gross disease [10, 17–19], the recent trend in head neck
cancer IMRT is to generally reduce boost PTV margins
around the gross tumor volume (GTV, e.g. EORTC trial
1219, also e-book N.Y. Lee, J.J. Lu, Target Volume De-
lineation and Field Setup, 317 DOI 10.1007/978-3-642-
28860-9, 2013) [17]. The anatomical patterns of neck
failure and persistence in our no-PND and hPR subgroup
confirmed this fact. Similarly, Garden et al. [5] found only
2 % (12/776) of definitive IMRT (±chemotherapy) pa-
tients with loco-regional recurrences outside the high-dose
target volumes after a median follow-up of 54 months. 3 %
(64/2124) of all dissected nodes in our PND cohort con-
tained residual viable tumor, which raises again the on-
going debate on the required extent of neck dissection.
Robbins et al. [20] conducted a prospective study on 84
patients who underwent neck dissection (radical or mod-
ified radical neck dissection vs selective neck dissection vs
super-selective neck dissection) for bulky nodal disease,
resulting in non-significantly different OAS and distant
metastasis free survival.
Isolated nodal relapse
Isolated nodal relapse is constantly reported being low
subsequent to PND as well as after radio-chemotherapy
alone. This was 1 % in the own PND cohort.
The Trans Tasman Radiation Oncology Group (TROG)
98.02 Study was determined to assess the incidence of
isolated nodal failure after radiation in 102 patients with
N2/3 disease and found zero isolated nodal failure without
a planned neck dissection, but 29/102 patients with distant
spread [21]. Garden et al. [5] assessed patterns of disease
recurrence following definitive IMRT in 776 oropharyn-
geal cancer patients treated between 2000 and 2007 and
found 3 % isolated nodal recurrences (N0: 88, N1/x: 140,
N2a/b: 370, N2c: 122, N3: 56). Similarly, many other
centers reported low rates\5 % [1–4, 6, 14, 20].
In our no-PND cohorts this was 27 %, of which*80 %
were cured by salvage surgery. Adams et al. [23] reported
isolated nodal failure of 6 % in 33 irradiated patients with
N3 status with neck dissection in 4 cases. The authors
concluded that the predominant pattern of relapse is
metastatic (30 %), and therefore intensification of systemic
therapy rather than loco-regional therapy should be ex-
plored. Alternatively, reducing the radiation dose to the
nodal GTV and the elective volumes may be another option
to decrease treatment intensity without compromising on-
cological outcome.
Salvage neck dissection
In 75 % of our small isolated neck relapse cohort (n = 28,
Fig. 2), successful salvage surgery was achieved. Similar-
ly, Deschamps et al. [23] reported from a tumor registry
based study on 224 (35 %) patients with disease recur-
rences out of 1291 who were irradiated between 1998 and
2007. 47/224 (21 %) patients presented with isolated neck
recurrence. Lee and her team assessed 260 nodally positive
head neck cancer patients treated with definitive radiation
(-chemotherapy) who all underwent observation only after
a negative PET–CT scan 6–24 weeks post-radiation. 4/260
patients (2.3 %) developed isolated neck relapse, of which
3/4 underwent successful salvage neck dissection. In 4/16
who underwent post-radiation ND because of negative
PET–CT but clinical suspicion ± positive CT or MRI,
residual nodal disease was found; all patients achieved
regional control [6].
Conclusion
Considering the facts of most neck relapses occurring in
the prior GTV, isolated nodal failure counting for *25 %
of nodal relapses after IMRT only, of which*80 % can be
salvaged, reduction of the radiation dose to nodal metas-
tases provided for PND, and/or a more restrictive approach
to PND may be suggested.
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